Tecentriq atezolizumab: Updated Phase Ib data

Updated data from a cohort of 32 evaluable patients with metastatic triple-negative breast cancer (TNBC) in an open-label, U.S. Phase Ib trial showed that 800

Read the full 257 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE